TERT promoter mutations: A novel independent prognostic factor in primary glioblastomas

Neuro-Oncology

Volumn 17, Issue 1, 2015, Pages 45-52

  Simon, Matthias ^a   Hosen, Ismail ^b   Gousias, Konstantinos ^a   Rachakonda, Sivaramakrishna ^b   Heidenreich, Barbara ^b   Gessi, Marco ^a   Schramm, Johannes ^a   Hemminki, Kari ^b,c   Waha, Andreas ^a   Kumar, Rajiv ^b  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c LUND UNIVERSITY   (Sweden)

Author keywords

MGMT; Primary glioblastoma multiforme; Prognostic factor; TERT mutation

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TELOMERASE REVERSE TRANSCRIPTASE; TEMOZOLOMIDE; DNA LIGASE; DNA METHYLTRANSFERASE; MGMT PROTEIN, HUMAN; TELOMERASE; TERT PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADULT; ALLELE; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; DNA METHYLATION; DNA POLYMORPHISM; ELECTRONIC MEDICAL RECORD; FEMALE; GENE MUTATION; GENOTYPE; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PROSPECTIVE STUDY; PYROSEQUENCING; SOMATIC MUTATION; AGED; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MUTATION; PROGNOSIS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GENOTYPE; GLIOBLASTOMA; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROMOTER REGIONS, GENETIC; TELOMERASE; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84922513709     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou158     Document Type: Article

References (35)

1. Dolecek TA, Propp JM, Stroup NE, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol. 2012;14(Suppl 5): v1-v49.
2. Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res. 2013;19(4):764-772.
3. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
4. Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006;7(5):392-401.
5. Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg. 2011; 115(1):3-8.
6. Malmstrom A, Gronberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012;13(9): 916-926.
7. Boldrini L, Pistolesi S, Gisfredi S, et al. Telomerase activity and hTERT mRNA expression in glial tumors. Int J Oncol. 2006;28(6): 1555-1560.
8. Lotsch D, Ghanim B, Laaber M, et al. Prognostic significance of telomerase-associated parameters in glioblastoma: effect of patient age. Neuro Oncol. 2013;15(4):423-432.
9. Langford LA, Piatyszek MA, Xu R, et al. Telomerase activity in human brain tumours. Lancet. 1995;346(8985):1267-1268.
10. Harada K, Kurisu K, Tahara H, et al. Telomerase activity in primary and secondary glioblastoma multiforme as a novel molecular tumor marker. J Neurosurg. 2000;93(4):618-625.
11. Simon M, Park TW, Leuenroth S, et al. Telomerase activity and expression of the telomerase catalytic subunit, hTERT, in meningioma progression. J Neurosurg. 2000;92(5):832-840.
12. Aubert G, Lansdorp PM. Telomeres and aging. Physiol Rev. 2008; 88(2):557-579.
13. Gunes C, Rudolph KL. The role of telomeres in stem cells and cancer. Cell. 2013;152(3):390-393.
14. Huang FW, Hodis E, Xu MJ, et al. Highly recurrent TERT promoter mutations in human melanoma. Science. 2013;339(6122): 957-959.
15. Horn S, Figl A, Rachakonda PS, et al. TERT promoter mutations in familial and sporadic melanoma. Science. 2013;339(6122): 959-961.
16. Arita H, Narita Y, Fukushima S, et al. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathol. 2013;126(6):267-276.
17. Killela PJ, Reitman ZJ, Jiao Y, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A. 2013; 110(15):6021-6026.
18. Vinagre J, Almeida A, Populo H, et al. Frequency of TERT promoter mutations in human cancers. Nat Commun. 2013;4:2185.
19. Nonoguchi N, Ohta T, Oh JE, et al. TERT promoter mutations in primary and secondary glioblastomas. Acta Neuropathol. 2013; 126(6):931-937.
20. Koelsche C, Sahm F, Capper D, et al. Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathol. 2013;126(6):907-915.
21. Shete S, Hosking FJ, Robertson LB, et al. Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet. 2009; 41(8):899-904.
22. Rajaraman P, Melin BS, Wang Z, et al. Genome-wide association study of glioma and meta-analysis. Hum Genet. 2012;131(12): 1877-1888.
23. Sanson M, Hosking FJ, Shete S, et al. Chromosome 7p11.2 (EGFR) variation influences glioma risk. Hum Mol Genet. 2011;20(14): 2897-2904.
24. Simon M, Hosking FJ, Marie Y, et al. Genetic risk profiles identify different molecular etiologies for glioma. Clin Cancer Res. 2010; 16(21):5252-5259.
25. Rachakonda PS, Hosen I, de Verdier PJ, et al. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc Natl Acad Sci U S A. 2013;110(43):17426-17431.
26. Hsu CP, Hsu NY, Lee LW, et al. Ets2 binding site single nucleotide polymorphism at the hTERT gene promotereffect on telomerase expression and telomere length maintenance in non-small cell lung cancer. Eur J Cancer. 2006;42(10):1466-1474.
27. Hartmann C, Hentschel B, Simon M, et al. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations. Clin Cancer Res. 2013;19(18): 5146-5157.
28. Mikeska T, Bock C, El-Maarri O, et al. Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis. J Mol Diagn. 2007;9(3): 368-381.
29. Muller T, Gessi M, Waha A, et al. Nuclear exclusion of TET1 is associated with loss of 5-hydroxymethylcytosine in IDH1 wild-type gliomas. Am J Pathol. 2012;181(2):675-683.
30. Jafri NF, Clarke JL, Weinberg V, et al. Relationship of glioblastoma multiforme to the subventricular zone is associated with survival. Neuro Oncol. 2013;15(1):91-96.
31. Liu XY, Gerges N, Korshunov A, et al. Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/ IDH2 and TP53 mutations. Acta Neuropathol. 2012;124(5): 615-625.
32. Xu D, Dwyer J, Li H, et al. Ets2 maintains hTERT gene expression and breast cancer cell proliferation by interacting with c-Myc. J Biol Chem. 2008;283(35):23567-23580.
33. Beesley J, Pickett HA, Johnatty SE, et al. Functional polymorphisms in the TERT promoter are associated with risk of serous epithelial ovarian and breast cancers. PLoS One. 2011;6(9):e24987.
34. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352(10):997-1003.
35. Wick W, Platten M, Meisner C, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012; 13(7):707-715.